If you are experiencing problems downloading PDF or HTML fulltext, our helpdesk recommend clearing your browser cache and trying again. If you need help in clearing your cache, please click here . Still need help? Email email@example.com
Radiofrequency (RF) ablation has gained great popularity in the treatment of Hepatocellular Carcinoma (HCC) on cirrhosis and is replacing Percutaneous Ethanol Injection (PEI) in treating 3cm or less HCC nodules. Its necrotic effect is more predictable than that of PEI and therefore RF can achieve a longer local tumor progression control and survival. In the last four years many data on its efficacy have been added in the Literature and long-term results on 3-5-year survival are available. In this review article data of the last 4 years on percutaneous RF ablation of HCC on cirrhosis are discussed in order to give an answer to questions put forward on this matter at 2000 EASL Barcelona Consensus Conference. Moreover, new perspectives in the percutaneous treatment of some form of advanced HCC (the so-called percutaneous thrombectomy) are presented together with some patents in the treatment of HCC.
Recent Patents on Anti-Cancer Drug Discovery publishes review articles on recent patents in the field of anti-cancer drug discovery e.g. novel bioactive compounds, analogs & targets. A selection of important and recent patents on anti-cancer drug discovery is also included in the journal. The journal is essential reading for all researchers involved in anti-cancer drug design and discovery.